The clinical use of antibodies in haematological malignancies

被引：5

作者：

Lopez-Guillermo, A. ^{[1
]}

Mercadal, S. ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷

关键词：

D O I：

10.1093/annonc/mdm294

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：51 / 57

页数：7

共 75 条

[1] Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach [J].

Abramson, JS ;

Shipp, MA .

BLOOD, 2005, 106 (04) :1164-1174

[2] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].

Bellosillo, B ;

Villamor, N ;

López-Guillermo, A ;

Marcé, S ;

Esteve, J ;

Campo, E ;

Colomer, D ;

Montserrat, E .

BLOOD, 2001, 98 (09) :2771-2777

[3] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].

Berinstein, NL ;

Grillo-Lopez, AJ ;

White, CA ;

Bence-Bruckler, I ;

Maloney, D ;

Czuczman, M ;

Green, D ;

Rosenberg, J ;

McLaughlin, P ;

Shen, D .

ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001

[4] Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].

Bohen, SP ;

Troyanskaya, OG ;

Alter, O ;

Warnke, R ;

Botstein, D ;

Brown, PO ;

Levy, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930

[5]

Burnett Alan K, 2002, Rev Clin Exp Hematol, V6, P26

[6]

Buske C, 2006, BLOOD, V108, p146A

[7] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[8] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

[9] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[10] Monoclonal antibody therapy for lymphoma [J].

Campbell, P ;

Marcus, R .

BLOOD REVIEWS, 2003, 17 (03) :143-152

← 1 2 3 4 5 6 7 8 →